In this episode, Daniel J. Kuritzkes, MD, reviews key clinical trial data and gives practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure. The overview will include analyses of:ATLAS and FLAIR studies of long-acting injectable CAB + RPVATLAS 2M dosing studyFDA approval and DHHS statement on use of long-acting injectable ARTStudies on whether an oral lead-in is neededPresenter:Daniel R. Kuritzkes, MDChief, Division of Infectious DiseasesBrigham and Women’s HospitalHarriet Ryan Albee Professor of MedicineHarvard Medical SchoolBoston, MassachusettsFollow along with the slides at:https://bit.ly/3hNfHIISee the entire program at:https://bit.ly/2TXTYWx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related